ARENA PHARMACEUTICALS INC's ticker is ARNA and the CUSIP is 040047607. A total of 258 filers reported holding ARENA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $49,320,000 | +56.1% | 530,670 | 0.0% | 10.96% | +48.9% |
| Q3 2021 | $31,601,000 | -8.4% | 530,670 | +4.9% | 7.36% | +1.7% |
| Q2 2021 | $34,487,000 | +32.2% | 505,670 | +34.5% | 7.23% | +34.2% |
| Q1 2021 | $26,082,000 | -1.6% | 375,870 | +8.9% | 5.39% | +25.1% |
| Q4 2020 | $26,516,000 | -64.4% | 345,120 | -65.4% | 4.31% | -35.8% |
| Q3 2020 | $74,558,000 | -9.1% | 996,898 | -23.5% | 6.71% | +2.3% |
| Q2 2020 | $81,986,000 | +403.8% | 1,302,399 | +236.1% | 6.55% | +285.5% |
| Q1 2020 | $16,275,000 | +23.6% | 387,499 | +28.3% | 1.70% | -6.8% |
| Q2 2018 | $13,167,000 | -100.0% | 302,000 | -77.1% | 1.82% | -76.5% |
| Q1 2018 | $52,187,000,000 | +130409.9% | 1,321,187 | +12.2% | 7.75% | +13.6% |
| Q4 2017 | $39,987,000 | +15.5% | 1,177,119 | -13.3% | 6.82% | +1.3% |
| Q3 2017 | $34,624,000 | -15.9% | 1,357,800 | -44.4% | 6.74% | -8.7% |
| Q2 2017 | $41,162,000 | – | 2,439,930 | – | 7.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 163,133 | $7,467,000 | 4.14% |
| PFM Health Sciences, LP | 2,271,536 | $103,968,000 | 3.07% |
| Partner Investment Management, L.P. | 28,877 | $1,322,000 | 2.26% |
| Atika Capital Management LLC | 181,000 | $8,284,000 | 1.74% |
| DAFNA Capital Management LLC | 93,942 | $4,300,000 | 1.62% |
| Asymmetry Capital Management, L.P. | 16,272 | $745,000 | 1.60% |
| First Light Asset Management, LLC | 190,838 | $8,735,000 | 1.32% |
| Perceptive Advisors | 953,129 | $43,624,000 | 1.18% |
| Rhenman & Partners Asset Management AB | 155,000 | $7,094,000 | 0.89% |
| Opus Point Partners Management, LLC | 9,770 | $447,000 | 0.81% |